AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA

CLOSED

PIAZZALE LUDOVICO ANTONIO SCURO 10, Verona, Italywww.ospedaleuniverona.it/ecm/homePrivateEstablished: 1426-01-01

Also known as:

aoui

sezione di psichiatria

dipartimento scienze morfologico biomediche

Clinical Trials

121

29 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1426

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

40.5%

Phase 1

15.7%

Phase 3

8.3%

Phase 2

5.0%

Phase 4

5.0%

Trial Status Distribution

Active, not recruiting

19.0%

Completed

33.1%

Not yet recruiting

5.0%

Recruiting

19.8%

Suspended

0.8%

Terminated

2.5%

Unknown

19.8%

Clinical Trials

Trials sponsored by this organization (121)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial. PIPAC_VEROne

Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis

Phase 4

Recruiting

60 participants

An open-label study to evaluate the safety and tolerability of inhaled Teicoplanin in the treatment of Staphylococcus aureus (including mrsa) infections in cystic fibrosis patients

Phase 2

Recruiting

12 participants

Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis

Phase 4

Recruiting

40 participants

Prospective, open-label, non-randomized, single-arm, dose titration study to investigate the efficacy and safety of IncobotulinumtoxinA in children deemed to require a total body dose up to 22U/kg (maximum dose 550U) during the study period for the treatment of upper and lower limb spasticity due to cerebral palsy

Phase 2

Recruiting

30 participants

Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study

Exploratory study to evaluate the safety and tolerability of tamoxifen citrate in the treatment of cystic fibrosis in patients without mutations currently eligible for therapy with CFTR modulator drugs

Phase 2

Recruiting

35 participants

Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)

Phase 2

Recruiting

Sep 2026150 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations